Table 1. Antibodies used.
Antibody | Clone | Titre | Company |
---|---|---|---|
Anti-CDX2 | CDX-88 | 1 : 50 | Biogenex, San Ramon, CA, USA |
Anti-CK7 | OVT-TL 12/30 | 1 : 100 | Dako, Carpinteria, CA, USA |
Anti-CK20 | KS20.8 | 1 : 4000 | Dako, Carpinteria, CA, USA |
Anti-EGFR | 31G7 | 1 : 50 | Invitrogen, Inc., Carlsbad, CA, USA |
Anti-HER2 | neu Ab8 | 1 : 300 | Labvision, Inc., Fremont, CA, USA |
Anti-MLH-1 | G168-15 | 1 : 25 | BD Biosciences, San Jose, CA, USA |
Anti-MSH-2 | FE11 | 1 : 100 | Calbiochem, Inc., Gibbstown, NJ, USA |
Anti-MSH-6 | 44 | 1 : 300 | BD Biosciences, San Jose, CA, USA |
Anti-PMS2 | A16-4 | 1 : 125 | BD Biosciences, San Jose, CA, USA |
Anti-PTEN | 28H6 | 1 : 100 | Novacastra, Bannockburn, IL, USA |
Anti-VEGF-A | VEGF A20 | 1 : 10 | Santa Cruz Biotechnology, Santa Cruz, CA, USA |
Abbreviations: CDX2=caudal type homeobox transcription factor 2; EGFR=epidermal growth factor receptor; MLH-1=MutL homologue 1; MSH-2=MutS homologue 2; PMS2=post meiotic segregation increased 2; PTEN=phosphatase and tensin homologue mutated on chromosome 10; VEGF-A=vascular endothelial growth factor A.